On-going HSG Research Studies & Clinical Trials
SIGNAL: A Phase II research trial for people who are at risk for Huntington Disease (HD) and have early signs of HD. The study will assess the safety, tolerability, and effectiveness of VX15 (a novel monoclonal antibody).
LEGATO-HD: a multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of laquinimod (0.5, 1.0, and 1.5 mg/day) as treatment in patients with Huntington's Disease.
PRIDE-HD is a Phase II clinical research study of an investigational drug called pridopidine in people who have a diagnosis of Huntington disease (HD). Pride-HD is a joint collaboration between the Huntington Study Group (HSG) and the European Huntington’s Disease Network (EHDN), with sponsorship by Teva Branded Pharmaceutical Products.
Pride-HD is ongoing, but no longer enrolling.
SD-809 (Auspex Pharmaceuticals)
“Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease.”
SD-809 is an investigational study drug developed by Auspex Pharmaceuticals for the treatment of chorea. First-HD and ARC-HD are Phase III clinical trials that are evaluating SD-809’s safety, tolerability and effectiveness in reducing chorea.
First-HD is designed for subjects who have not taken tetrabenazine in the past 6 months (no longer enrolling study participants).
ARC-HD is for subjects who are currently taking tetrabenazine or those who participated in First-HD (no longer enrolling study participants).
All participants are eligible for reimbursement of travel and lodging costs. Participants in ARC-HD may be eligible to receive at no cost the study drug and medical supervision for at least 12 months.
PREDICT-HD 2.0 - Observational research study for at-risk gene positive, pre-symptomatic, and gene negative tested individuals, with headquarters at the University of Iowa, under the leadership of Dr. Jane Paulsen.
Recently Completed HSG Research Studies & Clinical Trials
CREST-E: A global, multi-center, clinical trial run in collaboration with Massachusetts General Hospital investigating the effects of creatine monohydrate on the progression of Huntington disease, led by Dr. Steven Hersch.
2CARE: A multi-center, randomized, double-blind, placebo-controlled trial led by Merit Cudkowicz, Michael McDermott, and Karl Kieburtz, assesing the effects of coenzyme Q10 on inviduals with mild-to-moderate Huntington disease.
Reach2HD - A clinical research trial investigating the effects of PBT2 on invidividuals with early to mid-stage Huntington disease, led by Ray Dorsey of Johns Hopkins University and Diana Rosas of Massachusetts General Hospital.
PREQUEL: A clinical trial investigating the safety and tolerability of coenzyme Q10 for individuals with pre-manifest Huntington disease, led by Dr. Christopher Ross (John Hopkins University) and co-led by Dr. Kevin Biglan (University of Rochester).